Literature DB >> 33993978

Management and outcomes for long-segment Hirschsprung disease: A systematic review from the APSA Outcomes and Evidence Based Practice Committee.

Akemi L Kawaguchi1, Yigit S Guner2, Stig Sømme3, Alexandria C Quesenberry4, L Grier Arthur5, Juan E Sola6, Cynthia D Downard7, Rebecca M Rentea8, Patricia A Valusek9, Caitlin A Smith10, Mark B Slidell11, Robert L Ricca12, Roshni Dasgupta13, Elizabeth Renaud14, Doug Miniati15, Jarod McAteer16, Alana L Beres17, Julia Grabowski18, Shawn D St Peter19, Ankush Gosain20.   

Abstract

OBJECTIVE: Long-Segment Hirschsprung Disease (LSHD) differs clinically from short-segment disease. This review article critically appraises current literature on the definition, management, outcomes, and novel therapies for patients with LSHD.
METHODS: Four questions regarding the definition, management, and outcomes of patients with LSHD were generated. English-language articles published between 1990 and 2018 were compiled by searching PubMed, Scopus, Cochrane Central Register of Controlled Trials, Web of Science, and Google Scholar. A qualitative synthesis was performed.
RESULTS: 66 manuscripts were included in this systematic review. Standardized nomenclature and preoperative evaluation for LSHD are recommended. Insufficient evidence exists to recommend a single method for the surgical repair of LSHD. Patients with LSHD may have increased long-term gastrointestinal symptoms, including Hirschsprung-associated enterocolitis (HAEC), but have a quality of life similar to matched controls. There are few surgical technical innovations focused on this disorder.
CONCLUSIONS: A standardized definition of LSHD is recommended that emphasizes the precise anatomic location of aganglionosis. Prospective studies comparing operative options and long-term outcomes are needed. Translational approaches, such as stem cell therapy, may be promising in the future for the treatment of long-segment Hirschsprung disease.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aganglionosis; Hirschsprung; Level 3; Level 4; Level of Evidence; Long-segment; Outcome; Surgery

Mesh:

Year:  2021        PMID: 33993978      PMCID: PMC8552809          DOI: 10.1016/j.jpedsurg.2021.03.046

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.549


  74 in total

1.  Total colonic Hirschsprung's disease: a 28-year experience.

Authors:  Barbara E Wildhaber; Daniel H Teitelbaum; Arnold G Coran
Journal:  J Pediatr Surg       Date:  2005-01       Impact factor: 2.545

2.  Total colectomy and straight ileo-anal soave endorectal pull-through: personal experience with 42 cases.

Authors:  P Dodero; P Magillo; P L Scarsi
Journal:  Eur J Pediatr Surg       Date:  2001-10       Impact factor: 2.191

3.  Primary laparoscopic-assisted endorectal colon pull-through for Hirschsprung's disease: a new gold standard.

Authors:  K E Georgeson; R D Cohen; A Hebra; J Z Jona; D M Powell; S S Rothenberg; E P Tagge
Journal:  Ann Surg       Date:  1999-05       Impact factor: 12.969

4.  Long-term stooling patterns in infants undergoing primary endorectal pull-through for Hirschsprung's disease.

Authors:  D H Teitelbaum; R A Drongowski; J N Chamberlain; A G Coran
Journal:  J Pediatr Surg       Date:  1997-07       Impact factor: 2.545

5.  Functional outcome after operation for Hirschsprung disease--transanal vs transabdominal approach.

Authors:  Kjetil Juul Stensrud; Ragnhild Emblem; Kristin Bjørnland
Journal:  J Pediatr Surg       Date:  2010-08       Impact factor: 2.545

Review 6.  Hirschsprung-associated enterocolitis: prevention and therapy.

Authors:  Philip K Frykman; Scott S Short
Journal:  Semin Pediatr Surg       Date:  2012-11       Impact factor: 2.754

7.  Long-term clinical outcome in patients with total colonic aganglionosis: a 31-year review.

Authors:  Maria Menezes; Alessio Pini Prato; Vincenzo Jasonni; Prem Puri
Journal:  J Pediatr Surg       Date:  2008-09       Impact factor: 2.545

Review 8.  Clinical application of probiotics in the treatment of Helicobacter pylori infection--a brief review.

Authors:  Ami Patel; Nihir Shah; J B Prajapati
Journal:  J Microbiol Immunol Infect       Date:  2013-06-10       Impact factor: 4.399

9.  Development of a standardized definition for Hirschsprung's-associated enterocolitis: a Delphi analysis.

Authors:  Aimee C Pastor; Fahima Osman; Daniel H Teitelbaum; Michael G Caty; Jacob C Langer
Journal:  J Pediatr Surg       Date:  2009-01       Impact factor: 2.545

10.  Deriving human ENS lineages for cell therapy and drug discovery in Hirschsprung disease.

Authors:  Faranak Fattahi; Julius A Steinbeck; Sonja Kriks; Jason Tchieu; Bastian Zimmer; Sarah Kishinevsky; Nadja Zeltner; Yvonne Mica; Wael El-Nachef; Huiyong Zhao; Elisa de Stanchina; Michael D Gershon; Tracy C Grikscheit; Shuibing Chen; Lorenz Studer
Journal:  Nature       Date:  2016-02-10       Impact factor: 49.962

View more
  3 in total

1.  Reducing Underdiagnosis of Hirschsprung-Associated Enterocolitis: A Novel Scoring System.

Authors:  Ruth A Lewit; Laura V Veras; Robert A Cowles; Kathryn Fowler; Sebastian King; Eveline Lapidus-Krol; Jacob C Langer; Christine J Park; Fouad Youssef; Sergey Vavilov; Ankush Gosain
Journal:  J Surg Res       Date:  2021-01-15       Impact factor: 2.192

2.  A Novel Method for Identifying the Transition Zone in Long-Segment Hirschsprung Disease: Investigating the Muscle Unit to Ganglion Ratio.

Authors:  Wendy Yang; Jenny Pham; Sebastian K King; Donald F Newgreen; Heather M Young; Lincon A Stamp; Marlene M Hao
Journal:  Biomolecules       Date:  2022-08-10

Review 3.  Development, Diversity, and Neurogenic Capacity of Enteric Glia.

Authors:  Werend Boesmans; Amelia Nash; Kinga R Tasnády; Wendy Yang; Lincon A Stamp; Marlene M Hao
Journal:  Front Cell Dev Biol       Date:  2022-01-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.